Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Rainbow Children's Medicare Limited (RAINBOW.NS)
Hyderabad, IN
Rainbow Children's Medicare Limited is a leading Indian healthcare provider managing a network of multi-specialty hospitals dedicated to pediatric, obstetrics, and gynecology services. Its comprehensive child health offerings include general pediatrics, neonatology, various surgical disciplines, gastroenterology, hematology, oncology, psychology, dentistry, pulmonology, endocrinology, nephrology, nutrition, and psychiatric support. The company also delivers specialized care such as intensive care units, bone marrow and kidney transplants, cochlear implants, genetic and metabolic medicine, and therapeutic services like speech, language, and occupational therapy, alongside developmental and behavioral pediatrics. For women's health, Rainbow provides extensive obstetrics and gynecology services, including high-risk pregnancy management, painless delivery options, childbirth education, post-delivery support, well-woman check-ups, urogynecology, pre-pregnancy assessments, minimally invasive surgery, breast care, fetal medicine, and menopausal treatments. Furthermore, the company offers a full spectrum of fertility solutions, encompassing ovulation induction, various in-vitro fertilization techniques (such as ICSI and IMSI), intrauterine insemination, assisted hatching, cryopreservation, donor programs (sperm, oocyte, embryo), surgical sperm retrieval, and reproductive surgery. As of December 31, 2021, the company operated 14 hospitals and 3 clinics across 6 cities, providing a total of 1,500 beds. Established in 1998, its headquarters are situated in Hyderabad, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.98% | +1.65% | +9.31% | +13.25% | +0.73% | +2.88% | +0.04% | +45.33% | +201.64% | +201.64% | +201.64% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 8 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+12.4% ★ Q1'26: +24.3% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+15.0% Q1'26: +39.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+12.3% Q1'26: -20.6% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+23.1% ★ Q1'26: +22.6% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+14.6% ★ Q1'26: +17.7% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%-0.2% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×1.64× ★ Q1'26: 1.54× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 10 Rev. Ana. 9 EPS Ana. |
Mar 2027 10 Rev. Ana. 8 EPS Ana. |
Mar 2028 10 Rev. Ana. 9 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
11.74B
est: 12.01B (-2.3%)
|
12.97B
est: 13.40B (-3.2%)
|
15.16B
est: 15.37B (-1.4%)
|
16.74B
16.51B – 16.98B
+8.9% YoY
|
19.92B
19.08B – 20.51B
+19.0% YoY
|
23.08B
23.04B – 23.12B
+15.9% YoY
|
| EBITDA |
3.65B
est: 3.33B (+9.5%)
|
3.90B
est: 4.97B (-21.5%)
|
4.37B
est: 5.70B (-23.2%)
|
6.21B
6.12B – 6.30B
+8.9% YoY
|
7.38B
7.07B – 7.60B
+19.0% YoY
|
8.56B
8.54B – 8.57B
+15.9% YoY
|
| EBIT |
3.09B
est: 2.66B (+16.3%)
|
3.20B
est: 4.34B (-26.4%)
|
3.51B
est: 4.98B (-29.4%)
|
5.43B
5.35B – 5.50B
+8.9% YoY
|
6.46B
6.19B – 6.65B
+19.0% YoY
|
7.48B
7.47B – 7.49B
+15.9% YoY
|
| Net Income |
2.11B
est: 2.12B (-0.4%)
|
2.17B
est: 2.16B (+0.7%)
|
2.43B
est: 2.46B (-0.9%)
|
2.86B
2.74B – 2.99B
+16.7% YoY
|
3.30B
3.04B – 3.51B
+15.2% YoY
|
4.09B
3.42B – 5.20B
+23.8% YoY
|
| SGA |
406.32M
est: 1.41B (-71.2%)
|
3.36B
est: 1.57B (+113.5%)
|
504.09M
est: 1.81B (-72.1%)
|
1.97B
1.94B – 2.00B
+8.9% YoY
|
2.34B
2.24B – 2.41B
+19.0% YoY
|
2.71B
2.71B – 2.72B
+15.9% YoY
|
| EPS |
20.89
est: 20.81 (+0.4%)
|
21.38
est: 21.23 (+0.7%)
|
23.97
est: 24.34 (-1.5%)
|
27.96
26.98 – 29.35
+14.9% YoY
|
32.35
29.87 – 34.48
+15.7% YoY
|
39.59
33.60 – 51.11
+22.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Matthews Emerging Markets Discovery Active ETF MEMS MEMS | 0.77% | 172.3K | 0.99% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.06% | 458.9K | 0.65% |
| 3 | WisdomTree India Earnings Fund EPI | 0.00% | 69.0K | 0.84% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ramesh Kancharla D. Peds | Founder, Chairman, Managing Director and Chief of Gastro Enterology & Hepatology Unit | 46M | — |
| Dinesh Kumar Chirla MRCPCH | Whole-Time Director | 28M | — |
| Mahesh Madduri | Head of Strategy | — | male |
| Abrarali Dalal | Chief Executive Officer | — | male |
| Shreya Mitra | Company Secretary & Compliance Officer | — | female |
| Srinath Metla | Chief Strategy & Growth Officer | — | male |
| Vikas Maheshwari | Group Chief Financial Officer (KMP) | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RAINBOW.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
